Skip to main content
Acticor Biotech logo

Acticor Biotech — Investor Relations & Filings

Ticker · ALACT ISIN · FR0012519668 LEI · 969500K433EK1G89EV95 PA Manufacturing
Open in API
Filings indexed 200 across all filing types
Latest filing 2022-06-07 Share Issue/Capital Cha…
Country FR France
Listing PA ALACT

About Acticor Biotech

https://www.acticor-biotech.com

Acticor Biotech is a clinical-stage biopharmaceutical company that originated as a spin-off from the French National Institute of Health and Medical Research (INSERM). The company is dedicated to developing innovative treatments for thrombotic diseases, with a primary focus on the acute phase of ischemic stroke. Its lead drug candidate, glenzocimab, is a humanized monoclonal antibody fragment designed to target platelet glycoprotein VI (GPVI), a key receptor involved in thrombosis. The therapeutic approach aims to provide an effective anti-thrombotic effect to safely manage stroke patients without increasing the risk of bleeding, a significant complication associated with existing treatments.

Recent filings

Filing Released Lang Actions
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 98% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social au 31 mai 2022" (Monthly information relating to the total number of voting rights and shares comprising the share capital as of May 31, 2022). It explicitly references Article 223-16 of the AMF General Regulation and provides a table detailing the total number of shares and voting rights as of a specific date (May 31, 2022). This content directly relates to reporting changes in share capital and voting rights, which falls under the category of Share Issue/Capital Change (SHA) or potentially a general regulatory filing (RNS). However, since it specifically details the composition of the capital and voting rights, SHA is the most precise fit among the provided options, as it is a direct update on the capital structure components, even if it's a monthly regulatory requirement. It is not a dividend announcement (DIV), a director's dealing (DIRS), or a major shareholding notification (MRQ) which focuses on ownership thresholds. Given the focus on the total number of shares and voting rights, SHA is the best classification.
2022-06-07 French
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Disclosure of the total number of voting rights and shares as of May 31, 2022" and explicitly references French regulatory articles (Article L. 233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the French Financial Markets Authority - AMF). It provides a table detailing the number of shares and voting rights as of a specific date. This content directly relates to reporting changes in share capital structure and voting power, which falls under the category of Capital/Financing Update (CAP) or potentially a specific regulatory disclosure. However, given the focus on the total number of voting rights and shares, it is a specific type of capital structure disclosure. Reviewing the definitions, 'Share Issue/Capital Change' (SHA) covers announcements regarding new share issues or capital changes. While this is a disclosure of the *current* state of shares/rights rather than an *announcement* of a change, it is the closest fit among the provided options for a mandatory disclosure about the capital base. It is not a Director's Dealing (DIRS), Major Shareholding Notification (MRQ), or a general regulatory filing (RNS). Since it details the composition of the share capital, SHA is the most appropriate classification.
2022-06-07 English
Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...)
Regulatory Filings Classification · 95% confidence The document is a press release dated May 9, 2022, announcing the presentation of positive Phase 1b/2a study results (ACTIMIS) for the drug Glenzocimab at the ESOC 2022 conference. It details the presentation, provides context about the conference and the company (ACTICOR BIOTECH), and includes contact information. This format—an announcement of clinical/research results presented at a conference, often released to the public or investors—is characteristic of an Earnings Release (ER) if it were focused on financial performance, or more generally, a Regulatory Filing (RNS) if it doesn't fit a specific financial report category. Since it is announcing scientific/clinical progress rather than mandatory financial reporting (like 10-K, IR, or ER), and it is a formal announcement, it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for non-standard, yet important, corporate announcements. It is not a Call Transcript (CT), Investor Presentation (IP), or a formal Financial Report (10-K, IR). Given the context of announcing study results, it is a general corporate/regulatory announcement.
2022-05-09 French
Inside Information / Operations of the issuer (acquisitions, sales...)
Regulatory Filings Classification · 95% confidence The document is a press release dated May 9th, 2022, announcing the presentation of positive clinical trial results (ACTIMIS study) at a medical conference (ESOC 2022). It contains company updates, scientific details, and contact information, but it is not a formal regulatory filing like a 10-K, a comprehensive quarterly report (IR), or a specific financial announcement like a dividend notice or earnings release (ER). Since it is an announcement about company activity, scientific data presentation, and general corporate news, and does not fit the specific categories like AGM-R, 10-K, ER, or IR, it falls best under the general 'Regulatory Filings' (RNS) category as a miscellaneous regulatory/corporate announcement, or potentially an Investor Presentation (IP) if it were structured as slides, but given the format, RNS is the most appropriate fallback for a general corporate news release not covered elsewhere. However, since it is a detailed announcement of scientific/clinical progress, it is often categorized as Investor Presentation (IP) or a general Regulatory Filing (RNS). Given the context of presenting results, IP is a strong candidate, but RNS is the safest fallback for non-standard announcements. Let's re-evaluate against the definitions. It is not a formal presentation deck (IP), but a press release announcing the presentation. Therefore, RNS (Regulatory Filings - general regulatory announcements and fallback) is the most suitable classification for this type of corporate news release.
2022-05-09 English
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social au 30 avril 2022" (Monthly information relating to the total number of voting rights and shares comprising the share capital as of April 30, 2022). It explicitly references Article 223-16 of the AMF General Regulation and provides a table detailing the total number of shares and voting rights as of a specific date (30/04/2022). This content directly relates to the calculation and reporting of share capital and voting rights, which falls under the category of Major Shareholding Notification (MRQ) or potentially a specific regulatory filing. However, given the specific nature of reporting the total number of shares and voting rights monthly, this is a standard regulatory disclosure often categorized separately or as a specific type of capital update. Since the options include 'Major Shareholding Notification' (MRQ) which covers changes in significant ownership, and this document reports the total structure, it is closely related to capital structure reporting. Looking at the definitions, none perfectly match 'Monthly Voting Rights Report'. However, reporting changes in the total number of shares and voting rights is a fundamental disclosure related to the company's capital structure and ownership base. Given the options, 'Major Shareholding Notification' (MRQ) is the closest fit for disclosures related to the composition of the share base, although 'SHA' (Share Issue/Capital Change) is also related. Since this is a routine monthly update on the total count, and not a specific transaction (like a buyback or new issue), MRQ, which deals with ownership thresholds and structure reporting, is a reasonable classification, or RNS as a general regulatory filing. Since the content is highly specific to the share count and voting rights, and MRQ covers 'Notification of changes in significant share ownership levels (crossing thresholds)', this type of disclosure is often grouped with share structure reports. Given the French regulatory context, this is a mandatory disclosure under Article L. 233-8 II of the French Commercial Code. In the absence of a specific 'Voting Rights Report' code, and considering it details the structure of ownership, MRQ is the most appropriate fit among the provided choices for a disclosure detailing the share/voting structure, even if it's a routine update rather than a crossing event. If it were purely a general announcement, RNS would apply. I will classify it as MRQ due to the focus on the total share/voting structure.
2022-05-04 French
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Disclosure of the total number of voting rights and shares as of April 30, 2022" and explicitly references compliance with French Commercial Code and AMF regulations regarding the disclosure of the total number of shares and voting rights. This type of mandatory periodic disclosure, which details the capital structure and voting power, is most closely aligned with filings related to capital structure changes or major shareholding notifications. Since it is a specific, periodic disclosure about the total number of shares and voting rights, it fits best under the category related to share capital changes or major ownership changes. Given the options, 'Share Issue/Capital Change' (SHA) covers changes in the capital structure, and 'Major Shareholding Notification' (MRQ) covers changes in ownership thresholds. However, this specific disclosure is a mandatory statement of the *current* total number of shares and voting rights, which is often a component or precursor to other capital actions. In many regulatory frameworks, this specific type of disclosure (total share count update) is often grouped with capital structure updates. Since the document explicitly details the 'Number of shares making up the share capital' and 'Number of voting rights', the most appropriate classification among the provided specific codes is SHA (Share Issue/Capital Change), as it directly reports on the composition of the share capital. It is not a general regulatory filing (RNS) because a more specific category exists, and it is not a management/board change (MANG) or dividend announcement (DIV).
2022-05-04 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.